ETON PHARMACEUTICALS INC (ETON) Stock Price, Quote, News and Overview
NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD
ETON Quote, Performance and Key Statistics
14.43
-0.74 (-4.88%)
The current stock price of ETON is 14.43 USD. In the past month the price decreased by -15.53%. In the past year, price increased by 237.11%.
ETON Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 70.21 | 866.50B | ||
| JNJ | JOHNSON & JOHNSON | 16.6 | 399.26B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.84 | 390.81B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.4 | 240.25B | ||
| MRK | MERCK & CO. INC. | 12.3 | 237.79B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.22 | 222.93B | ||
| SNY | SANOFI-ADR | 14.49 | 148.98B | ||
| PFE | PFIZER INC | 8.44 | 148.70B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 52.79 | 122.06B | ||
| GSK | GSK PLC-SPON ADR | 8.24 | 80.20B | ||
| ZTS | ZOETIS INC | 28.25 | 75.46B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 34.09 | 47.56B |
Related stock screener links
About ETON
Company Profile
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 30 full-time employees. The company went IPO on 2018-11-09. The firm is focused on developing and commercializing treatments for rare diseases. The firm has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The firm has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.
Company Info
ETON PHARMACEUTICALS INC
21925 W Field Pkwy Ste 235
Deer Park ILLINOIS 60010 US
CEO: Sean E. Brynjelsen
Employees: 30
Company Website: https://etonpharma.com/
Investor Relations: http://ir.etonpharma.com
Phone: 18477877361
ETON PHARMACEUTICALS INC / ETON FAQ
What is the stock price of ETON PHARMACEUTICALS INC today?
The current stock price of ETON is 14.43 USD. The price decreased by -4.88% in the last trading session.
What is the ticker symbol for ETON PHARMACEUTICALS INC stock?
The exchange symbol of ETON PHARMACEUTICALS INC is ETON and it is listed on the Nasdaq exchange.
On which exchange is ETON stock listed?
ETON stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ETON PHARMACEUTICALS INC stock?
9 analysts have analysed ETON and the average price target is 26.18 USD. This implies a price increase of 81.43% is expected in the next year compared to the current price of 14.43. Check the ETON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ETON PHARMACEUTICALS INC worth?
ETON PHARMACEUTICALS INC (ETON) has a market capitalization of 384.27M USD. This makes ETON a Small Cap stock.
How many employees does ETON PHARMACEUTICALS INC have?
ETON PHARMACEUTICALS INC (ETON) currently has 30 employees.
What are the support and resistance levels for ETON PHARMACEUTICALS INC (ETON) stock?
ETON PHARMACEUTICALS INC (ETON) has a support level at 14.54 and a resistance level at 15.22. Check the full technical report for a detailed analysis of ETON support and resistance levels.
Is ETON PHARMACEUTICALS INC (ETON) expected to grow?
The Revenue of ETON PHARMACEUTICALS INC (ETON) is expected to grow by 18.46% in the next year. Check the estimates tab for more information on the ETON EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ETON PHARMACEUTICALS INC (ETON) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ETON, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ETON, evaluating the profitability, health, valuation and growth aspects
- ETON PHARMACEUTICALS INC (ETON) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ETON PHARMACEUTICALS INC (ETON) Sales and EPS estimates to see what analysts future expectations are.
- ETON PHARMACEUTICALS INC (ETON) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ETON PHARMACEUTICALS INC (ETON) Insider and Institutional Ownership to learn about the owners and their transactions.
- ETON PHARMACEUTICALS INC (ETON) Stock Chart to make your own analysis
- ETON PHARMACEUTICALS INC (ETON) Latest news and press-releases to stay up to date.
Does ETON PHARMACEUTICALS INC (ETON) stock pay dividends?
ETON does not pay a dividend.
When does ETON PHARMACEUTICALS INC (ETON) report earnings?
ETON PHARMACEUTICALS INC (ETON) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of ETON PHARMACEUTICALS INC (ETON)?
ETON PHARMACEUTICALS INC (ETON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).
What is the Short Interest ratio of ETON PHARMACEUTICALS INC (ETON) stock?
The outstanding short interest for ETON PHARMACEUTICALS INC (ETON) is 1.4% of its float. Check the ownership tab for more information on the ETON short interest.
ETON Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ETON. When comparing the yearly performance of all stocks, ETON is one of the better performing stocks in the market, outperforming 98.66% of all stocks.
ETON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ETON. While ETON seems to be doing ok healthwise, there are quite some concerns on its profitability.
ETON Financial Highlights
Over the last trailing twelve months ETON reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS decreased by -400% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.29% | ||
| ROE | -34.3% | ||
| Debt/Equity | 0 |
ETON Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ETON. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -115.34% and a revenue growth 18.46% for ETON